Julio C. Chávez
About
Julio C. Chávez is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics.
According to data from OpenAlex, Julio C. Chávez has authored 225 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 143 papers in Oncology, 122 papers in Pathology and Forensic Medicine and 73 papers in Genetics. Recurrent topics in Julio C. Chávez's work include Lymphoma Diagnosis and Treatment (122 papers), CAR-T cell therapy research (103 papers) and Chronic Lymphocytic Leukemia Research (69 papers). Julio C. Chávez is often cited by papers focused on Lymphoma Diagnosis and Treatment (122 papers), CAR-T cell therapy research (103 papers) and Chronic Lymphocytic Leukemia Research (69 papers). Julio C. Chávez collaborates with scholars based in United States, France and Spain. Julio C. Chávez's co-authors include Mohamed A. Kharfan‐Dabaja, Frederick L. Locke, Christina A. Bachmeier, Jorge J. Castillo, Lubomir Sokol, Samir Dalia, Bijal Shah, Sattva S. Neelapu, Michael D. Jain and Eduardo M. Sotomayor and has published in prestigious journals such as Circulation, Nature Medicine and Journal of Clinical Oncology.
In The Last Decade
Julio C. Chávez
198 papers receiving 3.1k citations
Hit Papers
Peers
Julio C. Chávez
Jakub Svoboda United States
Sunita D. Nasta United States
Craig S. Sauter United States
Timothy S. Fenske United States
Sindhu Cherian United States
Andreas Viardot Germany
David Wu United States
Kirit M. Ardeshna United Kingdom
Donald E. Tsai United States
Sarah K. Tasian United States
Citations per year, relative to Julio C. Chávez Julio C. Chávez (= 1×)
peers
Jakub Svoboda
Countries citing papers authored by Julio C. Chávez
Since
Specialization
Citations
This map shows the geographic impact of Julio C. Chávez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julio C. Chávez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julio C. Chávez more than expected).
Fields of papers citing papers by Julio C. Chávez
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Julio C. Chávez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julio C. Chávez. The network helps show where Julio C. Chávez may publish in the future.
Co-authorship network of co-authors of Julio C. Chávez
This figure shows the co-authorship network connecting the top 25 collaborators of Julio C. Chávez. A scholar is included among the top collaborators of Julio C. Chávez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julio C. Chávez. Julio C. Chávez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Chávez, Julio C., Michael Dickinson, Javier Muñoz, et al.. (2025). Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study. Blood. 145(20). 2303–2311.
2.
Mediavilla-Varela, Melanie, John J. Powers, Julio C. Chávez, et al.. (2025). Targeting S100A9-mediated inflammation: a novel therapeutic approach for CLL. Blood Advances. 9(20). 5219–5233.
3.
Simon‐Molas, Helga, Melanie Mediavilla-Varela, Julio C. Chávez, et al.. (2025). Mitigating T-cell mitochondrial dysfunction in CLL to augment CAR T-cell therapy: evaluation in an immunocompetent model. Blood Advances. 9(10). 2511–2529.
4.
Lancet, Jeffrey E., Rami S. Komrokji, Javier Pinilla‐Ibarz, et al.. (2024). Efficacy of Combination Blinatumomab and Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) and Chronic Myeloid Leukemia in Lymphoid Blast Phase (CMLBP) in a Real World Setting. Blood. 144(Supplement 1). 2820–2820.
5.
Chávez, Julio C., et al.. (2024). ABCL-440 Preliminary Safety and Efficacy Data of Combination Polatuzumab Vedotin Rituximab, Cyclophosphamide Adriamycin, Prednisone (Pola-R-CHP) in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) in the Standard-of-Care Setting: A Single-Center Experience. Clinical Lymphoma Myeloma & Leukemia. 24. S480–S480.
6.
Malpica, Luis, Mario L. Marques‐Piubelli, Brady Beltrán, et al.. (2024). EBV ‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2024 update on the diagnosis, risk‐stratification, and management. American Journal of Hematology. 99(10). 2002–2015.
7.
Michot, Jean‐Marie, Franck Morschhauser, Silvia Martina Ferrari, et al.. (2024). Longer Follow-up of Golcadomide (GOLCA), a Cereblon E3 Ligase Modulator (CELMoD™) Agent ± Rituximab (RTX), in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Blood. 144(Supplement 1). 869–869.
8.
Assouline, Sarit, Lihua E. Budde, Julio C. Chávez, et al.. (2024). Mosunetuzumab with polatuzumab vedotin: Subgroup analyses in patients (pts) with primary refractory or early relapsed large B-cell lymphoma (LBCL).. Journal of Clinical Oncology. 42(16_suppl). 7021–7021.
9.
Nastoupil, Loretta J., Manali Kamdar, Julio C. Chávez, et al.. (2023). LISOCABTAGENE MARALEUCEL (LISO‐CEL) VERSUS STANDARD OF CARE (SOC) AS SECOND‐LINE THERAPY IN LARGE B‐CELL LYMPHOMA (TRANSFORM STUDY): SUBGROUP ANALYSES BY PRIOR THERAPY RESPONSE. Hematological Oncology. 41(S2). 212–214.
10.
Whiting, Junmin, Michael Jaglal, Hayder Saeed, et al.. (2023). A Retrospective Study on Outcomes of Secondary CNS Lymphoma: Pattern of Relapse, Prognostic Factors, and Role of Consolidation Therapy. Blood. 142(Supplement 1). 1750–1750.
11.
Kharfan‐Dabaja, Mohamed A., et al.. (2023). Therapeutic options for large B-cell lymphoma relapsing after CD19-directed CAR T-cell therapy. Bone Marrow Transplantation. 59(2). 162–170.
12.
Amorrortu, Rossybelle P., Vonetta L. Williams, Vernon K. Sondak, et al.. (2022). History of keratinocyte carcinoma and survival after a second primary malignancy: the Moffitt Cancer Center patient experience. Journal of Cancer Research and Clinical Oncology. 149(7). 3607–3621.
13.
Martin, Peter, Nancy L. Bartlett, Julio C. Chávez, et al.. (2021). Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL. Blood. 139(8). 1147–1159.
14.
Lee, Dae Hyun, Sanjay Chandrasekhar, Michael D. Jain, et al.. (2021). Abstract 9828: Active Surveillance of Cardiotoxicity with Cardiac Biomarkers During Chimeric Antigen Receptor T-Cell Therapy. Circulation. 144(Suppl_1).
15.
Perez, Ariel Perez, Christina A. Bachmeier, Aleksandr Lazaryan, et al.. (2020). Factors Affecting Lymphocyte Collection Efficiency and Manufactured Product Specification during Leukapheresis for Diffuse Large B Cell Lymphoma Patients Treated with Commercial Tisagenlecleucel. Blood. 136(Supplement 1). 4–5.
16.
Dean, Erin, Rahul Mhaskar, Hong Lü, et al.. (2020). High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. Blood Advances. 4(14). 3268–3276.
17.
Sweet, Kendra, Rami S. Komrokji, Eric Padron, et al.. (2019). Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia. Clinical Cancer Research. 26(1). 54–60.
18.
Figura, Nicholas, Michael D. Jain, Austin J. Sim, et al.. (2019). Patterns of Failure Following Chimeric Antigen Receptor T-cell (CAR-T) Therapy. International Journal of Radiation Oncology*Biology*Physics. 105(1). S66–S67.
19.
Martin, Peter, Nancy L. Bartlett, María V. Revuelta, et al.. (2017). A Phase I, Open Label, Multicenter Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk, Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma. Blood. 130. 192–192.
20.
Chávez, Julio C.. (2005). Rinoplastia abierta, experiencias en el Hospital Clinicoquirúrgico «Hermanos Ameijeiras» (1997 a 2005). Revista cubana de cirugía. 44(4).
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Jakub Svoboda Breakdown of academic impact, for papers by Sunita D. Nasta Breakdown of academic impact, for papers by Craig S. Sauter Breakdown of academic impact, for papers by Timothy S. Fenske Breakdown of academic impact, for papers by Sindhu Cherian Breakdown of academic impact, for papers by Andreas Viardot Breakdown of academic impact, for papers by David Wu Breakdown of academic impact, for papers by Kirit M. Ardeshna Breakdown of academic impact, for papers by Donald E. Tsai Breakdown of academic impact, for papers by Sarah K. Tasian